Pharmacokinetics-Based Pediatric Dose Evaluation and Optimization Using Saliva - A Case Study

Area of Science:

• Pediatric Pharmacology
• Pharmacometrics
• Drug Metabolism

Background:

• Pediatric dosing requires understanding pharmacokinetics (PK).
• Plasma sampling in children is difficult, necessitating alternative PK sampling strategies.
• Metamizole is an analgesic used off-label in infants, requiring PK evaluation.

Purpose of the Study:

• To evaluate saliva as an alternative PK matrix for simplifying pediatric PK studies.
• To investigate the suitability of saliva for PK studies in infants using metamizole.
• To assess the feasibility of reduced plasma sampling scenarios.

Main Methods:

• Conducted a case study involving plasma and saliva PK sample collections after intravenous metamizole administration.
• Performed plasma/saliva pharmacometric (PMX) modeling of active metabolites 4-methylaminoantipyrine (4-MAA) and 4-aminoantipyrine (4-AA).
• Evaluated reduced plasma sampling scenarios using PMX simulations.

Main Results:

• Metamizole metabolite distribution between plasma and saliva was rapid.
• Estimated mean saliva/plasma fractions were 0.32 for 4-MAA and 0.57 for 4-AA.
• Saliva exhibited higher residual variability (47% for 4-MAA, 28% for 4-AA) compared to plasma (17% for 4-MAA, 11% for 4-AA).
• A simplified sampling scenario (6 saliva + 1 plasma sample) yielded PK parameter estimates similar to full plasma sampling.

Conclusions:

• Saliva shows increased PK variability compared to plasma for metamizole metabolites, limiting its use as a sole matrix in infant PK studies.
• Rich saliva sampling can decrease the number of required plasma samples for PK characterization.
• This approach facilitates PK studies to optimize pediatric drug dosing.